SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Feb 19, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Feb. 19, 2019 · CIK: 0001513525 · Accession: 0001213900-19-002773
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229615
Letter
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
February 19, 2019
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Todd Schiffman
Re: Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No: 333-229615
Ladies and Gentlemen:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-229615), be accelerated by the U.S. Securities and Exchange Commission to Wednesday, February 20, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant hereby authorizes its legal counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Adial Pharmaceuticals, Inc.
1001 Research Park
Blvd., Suite 100
Charlottesville, Virginia 22911
February 19, 2019
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Todd Schiffman
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No: 333-229615
Ladies and
Gentlemen:
Adial Pharmaceuticals,
Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement
on Form S-1, as amended (File No. 333-229615), be accelerated by the U.S. Securities and Exchange Commission to Wednesday,
February 20, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant hereby authorizes
its legal counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration.
Please contact Ms. Marlow at (516) 496-2223 or (516) 457-4238 with any questions you may have concerning this request, and please
notify her when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
By:
/s/ Willian B. Stilley III
Name:
William B. Stilley III
Title:
Chief Executive Officer
cc:
Leslie Marlow, Esq., Gracin & Marlow, LLP